tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Rhythm Pharmaceuticals: Buy Rating Backed by FDA Priority Review and Positive Phase 3 Results
PremiumRatingsRhythm Pharmaceuticals: Buy Rating Backed by FDA Priority Review and Positive Phase 3 Results
1M ago
Rhythm Pharmaceuticals announces FDA acceptance of sNDA for setmelanotide
Premium
The Fly
Rhythm Pharmaceuticals announces FDA acceptance of sNDA for setmelanotide
1M ago
Rhythm Pharmaceuticals Advances Genetic Obesity Treatment with Setmelanotide Study
Premium
Company Announcements
Rhythm Pharmaceuticals Advances Genetic Obesity Treatment with Setmelanotide Study
2M ago
Strong Q2 Performance and Strategic Investments Drive Buy Rating for Rhythm Pharmaceuticals
PremiumRatingsStrong Q2 Performance and Strategic Investments Drive Buy Rating for Rhythm Pharmaceuticals
2M ago
Rhythm Pharmaceuticals price target raised to $100 from $80 at H.C. Wainwright
Premium
The Fly
Rhythm Pharmaceuticals price target raised to $100 from $80 at H.C. Wainwright
2M ago
Rhythm Pharmaceuticals’ Earnings Call Highlights Growth and Challenges
Premium
Company Announcements
Rhythm Pharmaceuticals’ Earnings Call Highlights Growth and Challenges
2M ago
Rhythm Pharmaceuticals price target raised to $109 from $100 at Morgan Stanley
PremiumThe FlyRhythm Pharmaceuticals price target raised to $109 from $100 at Morgan Stanley
2M ago
Positive Outlook for Rhythm Pharmaceuticals: Strong Revenue Performance and Promising Future Catalysts Justify Buy Rating
Premium
Ratings
Positive Outlook for Rhythm Pharmaceuticals: Strong Revenue Performance and Promising Future Catalysts Justify Buy Rating
2M ago
Rhythm Pharmaceuticals reports Q2 EPS (75c), consensus (67c)
Premium
The Fly
Rhythm Pharmaceuticals reports Q2 EPS (75c), consensus (67c)
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100